CWP232291 for Acute Myeloid Leukemia

Phase 1 & 2

Waitlist Available

Research Sponsored by JW Pharmaceutical

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3rd cycle (each cycle = 28 days), cycle 1 day 1: pre, 0.5hr, 1hr, 2hr, 3hr, 4hr, 5hr, 8hr, and 24hr after the start of infusion in part a and at cycle 1 day 1: pre, 2hr, 4hr, 8hr, and 24hr after the start of infusion in part b.

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing a new drug to see if it is safe and effective in people with relapsed or refractory AML. The primary objective is to assess the efficacy of the drug in combination with another drug, cytarabine.

Eligible Conditions

Acute Myeloid Leukemia

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3rd cycle (each cycle = 28 days), cycle 1 day 1: pre, 0.5hr, 1hr, 2hr, 3hr, 4hr, 5hr, 8hr, and 24hr after the start of infusion in part a and at cycle 1 day 1: pre, 2hr, 4hr, 8hr, and 24hr after the start of infusion in part b.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3rd cycle (each cycle = 28 days), cycle 1 day 1: pre, 0.5hr, 1hr, 2hr, 3hr, 4hr, 5hr, 8hr, and 24hr after the start of infusion in part a and at cycle 1 day 1: pre, 2hr, 4hr, 8hr, and 24hr after the start of infusion in part b.

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3rd cycle (each cycle = 28 days), cycle 1 day 1: pre, 0.5hr, 1hr, 2hr, 3hr, 4hr, 5hr, 8hr, and 24hr after the start of infusion in part a and at cycle 1 day 1: pre, 2hr, 4hr, 8hr, and 24hr after the start of infusion in part b. for reporting.